MRI引导微波消融治疗早期肝细胞癌的疗效评估OA
Efficacy assessment of MRI-guided microwave ablation for the treatment of early-stage hepatocellular carcinoma
目的 探讨磁共振成像(MRI)引导微波消融(MWA)治疗早期肝细胞癌(HCC)的安全性和有效性.方法 回顾性纳入2016年1-12月于首都医科大学附属北京佑安医院肝病与肿瘤介入中心接受MRI引导MWA治疗的47例HCC患者,收集患者基线特征、手术参数、不良事件,并评估完全消融率、主要并发症发生率,1、3年及8年总生存(OS)率与无进展生存时间(PFS).采用Cox回归分析探讨预后相关因素.结果 47例患者,男42例,女5例,年龄37~39岁,平均(56.8±1.4)岁,肿瘤最大径为2.5(1.8,3.4)cm.MRI引导MWA消融成功率为100%,术后所有患者均出现丙氨酸氨基转移酶(ALT)和(或)天冬氨酸氨基转移酶(AST)轻度升高,经保肝治疗后均于1周内恢复正常,无Clavien-Dindo Ⅱ级及以上不良事件.患者1、3、8年OS率分别为100.0%,95.1%和82.4%,中位PFS为25(11,28)个月.结论 MRI引导MWA治疗HCC是一种安全、有效的微创治疗,具有理想的完全消融率和较低的并发症发生率,可获得良好的OS和PFS.
Objective To investigate the safety and efficacy of MRI-guided microwave ablation(MWA)in the treatment of early-stage hepatocellular carcinoma(HCC).Methods A retrospective analysis was conducted on 47 HCC patients who underwent MRI-guided MWA at Interventional Center for Liver Diseases and Oncology of Beijing Youan Hospital,Capital Medical University,between January and December 2016.Baseline characteristics,intraoperative procedural parameters,and adverse events were collected.Outcomes included complete ablation rate,incidence of major complications,1-,3-,and 8-year overall survival(OS)rates and progression-free survival(PFS).Cox regression analysis was performed to identify factors associated with prognosis.Results A total of 47 patients were recruited for this cohort,consisting of 42 males and 5 females.Age ranged from 37 to 79 years,with a mean age of(56.8±1.4)years.The median maximum tumor diameter was 2.5(1.8,3.4)cm.The complete ablation rate was 100%.All patients presented mild transient elevation of transaminases,and liver function recovered within one week after hepatoprotective treatment.No adverse events of Clavien-Dindo grade Ⅱ or higher occurred.The 1-,3-,and 8-year OS rates were 100.0%,95.1%and 82.4%,respectively,while the median PFS was 25(11,28)months.Conclusion MRI-guided MWA for HCC is a safe and effective minimally invasive treatment with a high complete ablation rate,a low complication rate,favorable long-term overall survival and progression-free survival.
马良;安奕轩;张卿;高文峰;何宁;杨晓珍;赵鹏;张永宏;袁春旺
首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069中国人民解放军总医院肝病医学部,北京 100143首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069首都医科大学附属北京佑安医院肝病与肿瘤介入中心,北京 100069
医药卫生
MRI引导微波消融肝细胞癌安全性有效性无进展生存
MRI-guidedmicrowave ablationhepatocellular carcinomasafetyefficacyiprogression-free survival
《肝胆胰外科杂志》 2026 (9)
622-625,4
首都卫生发展科研专项(2024-1-5041)科技创新2030——"新一代人工智能"重大项目(2021ZD0113200).
评论